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We review 6½ years of one of the world’s larg-
est programs for the prevention of mother-to-
child transmission (PMTCT) of HIV in resource-
limited settings. Created by the Elizabeth Glaser
Pediatric AIDS Foundation (EGPAF) in Septem-
ber 1999 and originally titled ‘‘Call to Action,’’
this multinational effort provides access to ser-
vices for PMTCT.
EGPAF’s PMTCT program was developed
on the basis of the results of clinical trial
HIVNET 012, which demonstrated the efficacy
of a feasible, effective, safe regimen of anti-
retroviral medication to reduce mother-to-child
transmission of HIV.1,2 This advance presented
the first real opportunity to narrow the gap
between wealthier and resource-poor nations
in preventing mother-to-child transmission.
Prior to HIVNET 012, the regimens that had
proven effective for PMTCT required antepar-
tum administration of zidovudine (AZT) for a
minimum of 4 weeks, during labor and deliv-
ery, and oral administration to the infant for at
least 1 week.3–5
In Uganda, single-dose nevirapine (NVP) was
reported to be more effective than were clinical
trials in the Ivory Coast and Burkina Faso that
used a 4-week antepartum course of AZT.4,5
Single-dose NVP could be administered orally
to pregnant HIV-positive women at the onset of
labor and to their infants within 72 hours after
delivery at a cost of less than US$4.1 Since
2000, Boehringer Ingelheim has donated NVP
to many countries for antiretroviral prophy-
laxis.6 The simplicity and affordability of single-
dose NVP stimulated a commitment by the
foundation to provide resources for the urgent
expansion of PMTCT services.
METHODS
EGPAF was cofounded in1988 by Elizabeth
Glaser, Susan DeLaurentis, and Susie Zeegen.7
It has developed and administered hundreds of
peer-reviewed research and implementation
programs worldwide.
In September 1999, the same month that
HIVNET 012 was published, EGPAF invested
$1 million to initiate a multicountry, service-
based programmatic effort in the developing
world to reduce perinatally acquired HIV in-
fection. Substantial contributions to the pro-
gram subsequently were provided from private
donors, including the Bill and Melinda Gates
Foundation. In 2002, EGPAF entered into an
agreement with the United States government
to expand access to and scale up PMTCT
services.
EGPAF solicited applications from govern-
mental, nongovernmental, faith-based, na-
tional, and international organizations and
health care facilities interested in planning,
implementing, or expanding PMTCT programs.
It engaged in a grant-making process that was
iterative, peer reviewed, and interactive with
the proposed project leaders.
EGPAF launched its first PMTCT projects in
Thailand and 5 African countries (South Africa,
Kenya, Uganda, Cameroon, and Rwanda) in
2000. As of June 2006, EGPAF has supported
projects in 22 countries: Angola, Cameroon,
China, Ivory Coast, Democratic Republic of
Congo, Dominican Republic, Georgia, Hondu-
ras, India, Kenya, Lesotho, Malawi, Mozam-
bique, Russia, Rwanda, South Africa, Swaziland,
Tanzania, Thailand, Uganda, Zambia, and
Zimbabwe. Published reports of EGPAF-sponsored
activities in Cameroon, Zambia, and Zimbabwe
are available.8–11
EGPAF-affiliated work is conducted in ac-
cordance with local ministry of health policies.
EGPAF-affiliated programs integrate HIV
counseling and testing and antiretroviral pro-
phylaxis regimens into existing maternal
and child health clinics. Patient flow, HIV
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counseled, and 82.8% of those counseled accepted testing. Among women
identified as HIV positive, 75.0% received antiretroviral prophylaxis (most a
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testing, supplying mothers with medication at time of diagnosis, and providing
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should be viewed as an achievable paradigm and an essential part of the
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counseling techniques and testing algorithms,
drug distribution, and other aspects of program
delivery differ among countries. EGPAF funds
have supported clinic renovation, essential
commodities, community mobilization and
training of health care workers, education on
infant feeding and family planning, technical
assistance, evaluation and monitoring, and
psychosocial support.
HIV Counseling
Commonly, women seeking prenatal care at
participating clinics receive general health ed-
ucation, including information about HIV and
primary prevention messages. Individual or
group pretest HIV counseling is provided to
pregnant women, a practice that is evolving to
an ‘‘opt-out’’ approach to testing. With the opt-
out approach, women are informed that HIV
testing is provided as part of an essential
package of standard antenatal care; they can
decline the test if they choose. The standard
antenatal care package typically includes test-
ing for syphilis, determination of hemoglobin
levels, treatment for malaria, administration of
vitamins and iron, tetanus immunization, and
urinalysis. Women have the right to refuse HIV
testing without affecting their access to other
services.
National policies determine who may pro-
vide pre- and posttest counseling. Nurse mid-
wives, nurses, physicians, medical officers,
trained nonmedical personnel, and trained
birth attendants are among those allowed to
provide services in some PMTCT locations.
All women receive individual posttest coun-
seling. Posttest counseling is more time-
consuming than was pretest counseling, given
the need to effectively tailor information for
women according to serostatus. During posttest
counseling, providers introduce the concept of
longitudinal care during pregnancy and after
delivery for both mother and infant. Address-
ing infant feeding options for mothers is im-
portant, because one third to one half of all
mother-to-child transmissions occur postnatally
through breastfeeding.12
HIV Testing
EGPAF-affiliated PMTCT programs perform
HIV testing in accordance with national poli-
cies for antenatal patients. Most facilities em-
ploy rapid HIV antibody testing using
Determine HIV-1/2 (Abbott Laboratories,
Abbott Park, IL), which has been donated to
many resource-limited countries, and most
provide same-day results, improving the per-
centage of women receiving test results.13 In a
minority of facilities, women return for a sep-
arate visit to learn their HIV serostatus. Most
countries currently employ serial testing.14 Na-
tional policies also determine whether nurses
or other personnel in the antenatal care or
labor and delivery areas can be trained and
certified to perform the HIV test.
Antiretroviral Prophylaxis With
Single-Dose Nevirapine
Most of EGPAF’s sites encourage HIV-
infected women to deliver in a facility with a
skilled birth attendant where they may be
given single-dose NVP under direct observa-
tion. However, many programs give single-dose
NVP to women during antenatal care, advising
them to take it at the onset of active labor.
Some programs have also started offering
women the infant dose of NVP before delivery,
so that it is available to be given by the woman
at home. The maternal single-dose NVP regi-
men is 200 mg, to be ingested at the onset of
labor. When infant weight cannot be obtained,
the infant dose is 0.6 mL (6 mg) of NVP syrup,
to be ingested within 72 hours after delivery;
otherwise, infant dose is 2 mg/kg.
Traditional birth attendants (trained and
untrained) are encouraged to train and partic-
ipate in PMTCT activities in areas in which they
provide pre- and postnatal care. Birth atten-
dants provide these services in Cameroon10,15
and Tanzania16 and are planned for Zambia.
An increasing number of our affiliated sites
counsel and test women who are in labor and
whose HIV status is unknown, either because
the women have not received antenatal care or
have received antenatal care without PMTCT
services. Those who test positive for HIV dur-
ing labor are offered NVP prophylaxis and
additional postpartum counseling.
Data Collection
EGPAF requires quantitative progress re-
ports either quarterly or semiannually,
depending on the funding source. Each facil-
ity records patient data in both antenatal clin-
ics and labor and delivery settings, with
data on counseling, testing, HIV status, and
antiretroviral prophylaxis, among other indi-
cators (for a list of indicators, see the appendix
available as a supplement to the online version
of this article at http://www.ajph.org). The
facility or program then submits a standardized
form to the in-country technical adviser or the
foundation program officer. EGPAF’s technical
assistance visits include assessing the clinic
service registers used to collect these data,
sampling data to ensure accuracy, and provid-
ing technical assistance to address findings or
concerns. Although every effort is made to
promote standardized definitions of key pro-
gram indicators related to PMTCT services,
such as counseling, testing, and distribution
of maternal and infant doses of antiretroviral
medication, there are sometimes subtle differ-
ences in these indicators according to national
polices and guidelines. These data, which
are collected at the facility level, represent
program results among the subset of women
seeking antenatal and labor and delivery
services.
The technical adviser or program officer
reviews and submits program data to EGPAF’s
monitoring and evaluation staff. EGPAF’s sci-
entific director reviews reports for inconsis-
tencies, trends over time, and variability be-
tween facilities, and provides feedback on
challenges and improvements. Queries are sent
to in-country technical staff or facility person-
nel for appropriate corrections.
EGPAF staff enter the quantitative data from
the progress reports, including corrections, in
Filemaker Pro 8 (FileMaker Inc, Santa Clara,
CA). Program staff in the United States collab-
oratively analyze the data and create summary
presentations to internal and external stake-
holders.
Technical Assistance
EGPAF provides on-site monitoring to pro-
grams at least once every 6 months. Technical
assistance was initially provided through a
contract with Family Health International, but
it is presently the responsibility of EGPAF itself.
Recommendations from consultants or EGPAF
staff are incorporated into the program and,
when appropriate, shared across facilities. Fa-
cilities also share technical expertise and les-
sons learned by visiting other facilities and
participating in a biannual program imple-
menters’ meeting.
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RESULTS
Over 6½ years, EGPAF’s multinational
PMTCT program increased significantly in
scope. Cumulatively, more than 2.6 million
women accessed antenatal services or were
eligible for PMTCT services in labor and de-
livery settings through June 2006 (Figure 1).
Overall, 92.9% of these women were coun-
seled and 82.8% of women counseled ac-
cepted testing. Among women identified
as HIV positive, 75.0% received antiretro-
viral prophylaxis, as did 45.6% of their
infants.
In 2000, 11753 pregnant women were seen
in antenatal clinics at 9 facilities in which the
EGPAF supported PMTCT. Most of these
women (93.7%) received counseling, and more
than half (68.3%) were tested for HIV, of
whom 86.9% received their results. The fol-
lowing year, there were 47 facilities with
EGPAF-supported PMTCT services and a
370% increase in the number of women ac-
cessing prenatal care. Of these women, 89.9%
received counseling and 81.1% were tested
for HIV, of whom 90.6% received their results.
In 2002, there was another 450% increase
in the number of women provided access to
PMTCT services at EGPAF-affiliated fa-
cilities, which now numbered 122; 82.3% of
these women were counseled, and 80.7% were
tested for HIV, of whom 83.8% received their
test results. Program growth continued
in 2003, when 2.4 times as many women as in
the previous year were seen in antenatal clinics
at 357 facilities; in 2004, when the number
of women accessing services at 613 facilities
grew 140% and in 2005, which saw 120%
growth in the number of women accessing
PMTCT services at EGPAF-affiliated facili-
ties, which now numbered 958 (Figures 2
and 3).
The most notable changes over time were
observed in maternal provision of HIV testing
and receipt of mother and infant doses of anti-
retroviral prophylaxis (Figure 4). A total of
84.9% of counseled women in antenatal care
and labor and delivery service received HIV
testing from July 1, 2005, through June 30,
2006, compared with 68.3% of the women
in 2000.
The greatest increases over time in uptake of
key PMTCT services were in documented re-
ceipt of antiretroviral prophylaxis by mothers
and infants. The percentage of women receiv-
ing antiretroviral prophylaxis was measured at
79.6% for the most recent year for which data
are available and 55.7% for the first year of
the program. A total of 56104 women were
reported to have received antiretroviral pro-
phylaxis in the most recent year; if provision
had remained at 55.7%, an estimated 39275
women would have received this critical ser-
vice during the same time period. Provision
of infant antiretroviral drug prophylaxis was
reported to be 52.3% in the last year and
31.2% in the first year. A total of 36859 doses
of infant prophylaxis were dispensed in the last
year. If provision in the last year had remained
at 31.2%, only 22000 infants would have
received prophylaxis.
Opt-Out Testing
The provision of universal counseling with
an opt-out approach to testing appears to
enhance use, as reported in Cameroon11 and
Malawi.17 The Malawi program, which receives
funding and technical support from EGPAF
and is administered by the University of North
Carolina, reported a cumulative 15.1% sero-
prevalence among pregnant women receiving
antenatal care services. On the basis of this rate,
7335 of the 48578 pregnant women seen
at the Malawi PMTCT facilities from January
2002 to December 2004 would be expected to
be HIV positive. The Malawi program used opt-
in testing, in which women are informed they
can elect to be counseled and tested for HIV if
they want (the test was not required in stan-
dard antenatal care). Using this approach,
4586 women were identified as HIV positive,
or only 62.5% of the estimated HIV-positive
women. Of these, 1964 women received anti-
retroviral prophylaxis (42.8% of those identi-
fied as HIV positive, but only 26.8% of those
estimated to be HIV positive).
In early 2005, the program implemented
universal group pretest counseling and opt-out
testing. From January 2005 through June
2006, the Malawi PMTCT program received
31797 pregnant women in their antenatal
clinics, of whom 4801would be predicted to be
HIV positive on the basis of a seroprevalence
rate of 15.1%. The program identified 4329
HIV-positive women, or 90.2% of the number
expected to be HIV positive. A total of 4564
HIV-positive women received antiretroviral
Note. Data shown (left to right) are as follows: women eligible for PMTCT services in antenatal care (ANC) and in labor and
delivery ward; women receiving counseling; women tested for HIV; women receiving their test results; women who were HIV
positive; women receiving antiretroviral (ARV) prophylaxis; infants receiving ARV prophylaxis.
FIGURE 1—Selected indicators showing cumulative results of the Elizabeth Glaser Pediatric
AIDS Foundation’s program for the prevention of mother-to-child transmission (PMTCT) of
HIV, through June 30, 2006.
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prophylaxis (over 100% of those identified as
HIV positive were reported to receive ARV
prophylaxis because this reporting window
included women identified as HIV positive
from the previous interval). Of the women
expected to be HIV positive, 95. 1% received
ARV prophylaxis. With the opt-out approach, a
substantial improvement from the first 2
years of the program was achieved.17
Services to Prevent Mother-to-Child
Transmission in Labor and Delivery
Settings
National PMTCT programs have recognized
the opportunity to provide counseling and
testing in the labor and delivery setting, and
some programs are introducing these services.
Including these services in labor and delivery
settings allows for identification of HIV-positive
women who have not received counseling
and testing in the antenatal setting. HIV coun-
seling and testing is offered to women ar-
riving in labor with unknown serostatus,
including women who did not attend an ante-
natal clinic or attended one without PMTCT
services.
In July 2005, EGPAF’s PMTCT program
started to document the number of eligible
women in labor and delivery settings in addi-
tion to the number of women in antenatal clinic
settings. From July 2005 to June 2006, a total
of 919975 women accessed the program’s
services, with 6.9% of them accessing services
only in labor and delivery. Percentages by
country of women accessing services only in
labor and delivery are as follows: Kenya, 7.8%
of 68034 women; Mozambique, 16.9% of
38772; Rwanda, 3.6% of 26729; Swaziland,
34.1% of 15787; and Tanzania, 16.0% of
102980.
Provision of Maternal and Infant
Nevirapine
Initially, most facilities dispensed NVP only
in labor and delivery settings when women
arrived for delivery. With the recognition that
some women may deliver at home or arrive too
late in labor to receive their NVP tablet, the
policy has changed so that facilities are en-
couraged to dispense NVP to the mother either
at a fixed point in gestation (such as at 28
weeks) or upon diagnosis of HIV.18 Significant
improvement in the percentage of HIV-positive
women receiving antiretroviral prophylaxis
upon diagnosis of HIV has been described for
Cameroon and Kenya.18
A pilot program in Tabora, Tanzania,
reported similar improvement with the policy
change. The program, which took place in
Nzega, Igunga, and Sikonge districts, compared
provision of antiretroviral prophylaxis for
HIV-positive women given a tablet at 28 weeks
gestation from April to June 2006 to provision
of prophylaxis at HIV diagnosis from July to
October 2006. The proportion of HIV-positive
women receiving antiretroviral prophylaxis
increased as follows: Nzega, from 42.9%
(116 of 270) to 94.9% (340 of 358); Igunga,
from 54.8% (96 of 175) to 102.9% (242 of
235); Sikonge, from 66.6% (80 of 120) to
102.0% (152 of 149). (Women who were
identified as HIV positive elsewhere but re-
ceived antiretroviral prophylaxis at EGPAF
sites are included in the numerator but not
the denominator, resulting in some per-
centages slightly higher than 100%.) Cumula-
tively, for Tabora, 52.6% of HIV-positive
women received antiretroviral prophylaxis
with the 28-week policy vs 99% with the
revised policy. Given the strong temporal rela-
tionship between the policy change and im-
provement in receipt of antiretroviral pro-
phylaxis, the data suggest that providing
NVP upon diagnosis of HIV improves the
provision of antiretroviral prophylaxis to
HIV-positive women.
In the program in Kericho, Kenya, upon
being diagnosed with HIV, pregnant women
are provided with a black plastic bag containing
a 200-mg tablet of NVP along with a NVP-filled
oral syringe wrapped in foil for them to ad-
minister to their infants shortly after delivery.18
During the data collection period (January 1–
March 31, 2005), before the intervention was
implemented, 72.7% of HIV-positive mothers
and 57.3% of their infants received NVP doses.
In the same quarter the following year, after the
intervention was put into place, 94.1% of
HIV-positive mothers and 85.7% of their
Note. ANC = antenatal care.
FIGURE 2—Number of women in the Elizabeth Glaser Pediatric AIDS Foundation’s program
for the prevention of mother-to-child transmission (PMTCT) of HIV who were eligible for
PMTCT services in antenatal care or labor and delivery ward, received counseling, received
HIV testing, and received HIV test results, by time interval.
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infants received doses of NVP. By comparison,
at other foundation African facilities in the same
time period, 78% of HIV-positive mothers




Our analyses are based on program data
reported to EGPAF. Data collection has proved
to be difficult over the life of the program.
When the program began, there were few
functioning national systems for monitoring
PMTCT; the data collection process for
EGPAF’s PMTCT program helped to inform
and shape the new national systems that were
implemented. Because data on infant feeding
are limited, they are not included here although
infant feeding is a critical issue. Reported data
on transmission rates have also been sparse;
further studies are needed to better understand
transmission rates in program settings. Despite
these limitations, a program of this size pro-
vides useful data that can help guide programs
locally and advocate for program expansion
nationally and internationally.
Conclusions
The value of PMTCT programs extends
beyond prevention of infant HIV infection.
These programs establish a foundation for
more-widespread antiretroviral therapy by
training health care providers, including those
in maternal and child health, enabling labora-
tory diagnosis of HIV, educating and counsel-
ing women about HIV, identifying infected
individuals, and educating community mem-
bers about preventing, transmitting, and treat-
ing HIV. These services have empowered
women to make decisions about their health
care and the care of their infants. They also
enhance systems for procurement and distri-
bution and create opportunities to integrate
HIV prevention and care services into the
health care infrastructure.
In many countries, EGPAF’s PMTCT pro-
gram was the first to distribute prophylactic
antiretroviral agents (primarily single-dose
NVP) as part of routine services in maternal
and child health clinics. EGPAF’s experience
demonstrates that several strategies can in-
crease access to and use of PMTCT services;
these include opt-out HIV testing, providing
maternal antiretroviral prophylaxis at the time
of HIV diagnosis, providing the infant with
antiretroviral prophylaxis in antenatal care,
and offering PMTCT services in labor and
delivery settings.18
Many maternal and child health clinics now
give single-dose NVP to the mother at the time
of diagnosis in an antenatal clinic, advising her
to take it at the onset of active labor. The
percentage of women receiving antiretroviral
prophylaxis at facilities supported by EGPAF
has increased over time (Figure 4). This in-
crease seems primarily attributable to the dis-
pensing of single-dose NVP at the time of
diagnosis in an antenatal clinic. Women pro-
vided NVP in an antenatal care clinic might not
be directly observed swallowing the dose.
There is no guarantee that all women will take
their medication, but women who do not de-
liver in a facility will have the opportunity to
take the medicine only if it is in their possession
at the onset of labor.18 Two published studies
have measured cord blood concentrations of
NVP after the medication was dispensed to
women in an antenatal clinic. The percentage
of women who took the medication when it
was distributed in this fashion was 68% in
Zambia and 94% in Uganda.19,20
Provision of the infant dose within 3 days
after delivery has been difficult when infants
are not born in a health care facility. The infant
NVP syrup is available in a 20-mL multiuse
bottle but is not available from the manufac-
turer in single-dose packaging. In an attempt to
improve the provision of NVP syrup by HIV-
exposed infants, an increasing number of fa-
cilities dispense the infant dose in an oral
syringe prefilled by the health care provider
when the mother is diagnosed with HIV in an
antenatal clinic. An oral syringe (Baxa Corpo-
ration, Englewood, CO) is part of Boehringer
Ingelheim’s NVP donation program, and NVP
has a demonstrated stability of 2 months
FIGURE 3—Number of women in the Elizabeth Glaser Pediatric AIDS Foundation’s
program for the prevention of mother-to-child transmission who tested positive for HIV and
the number of women and infants who received antiretroviral (ARV) prophylaxis, by time
interval.
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(according to the Boehringer Ingelheim pack-
age insert21) in the oral syringe.22
Although provision of PMTCT services dur-
ing labor poses additional operational chal-
lenges, it may contribute substantially to the
number of pregnant women identified as HIV-
positive and the number of women and infants
subsequently provided antiretroviral prophy-
laxis.18
Clinical trials in nonbreastfeeding popula-
tions have demonstrated that AZT initiated as
early as 12 weeks antepartum, with single-dose
NVP at onset of labor, reduces transmission to
1% to 2%,23 as does highly active antiretroviral
therapy24 or AZT delivered prior to an elective
cesarean delivery.25,26 Successful implementa-
tion of these regimens is more complex than
prophylaxis with a single drug.
The expert consultation panel of the World
Health Organization (WHO) recently updated
its guidelines for PMTCT to encourage the
adoption of more-complex and -efficacious
antiretroviral prophylaxis regimens, which may
decrease the perceived risk of the development
of virological resistance to NVP.27 The treat-
ment of immunocompromised (WHO Stage 3
or 4) HIV-infected women is emphasized in the
WHO guidelines. The criteria for initiation of
antiretroviral therapy for pregnant women are
the same as for nonpregnant women. Treating
these women addresses their health, substan-
tially decreases transmission to the infant, and
minimizes the development of resistance
to NVP from administration of single-dose
NVP.
It is essential to expand access to PMTCT
services into areas in which none currently
exist and, whenever possible, to provide more-
efficacious regimens. For many populations,
an essential step for providing these services
is access to single-dose NVP, with more-
complicated regimens added incrementally.
In many settings, single-dose NVP will con-
tinue to be the only feasible intervention in
the immediate future.
Antiretroviral prophylaxis has proven effi-
cacious in preventing mother-to-child trans-
mission of HIV. Seven years have passed since
the initiation PMTCT programs, but millions of
new infections have occurred in infants. Only
an estimated 34% of HIV-positive women in
the world have access to PMTCT services.28
It is important to obtain the requisite data to
substantiate different strategies while continu-
ing to expand access to these services. A sub-
stantial decrease in infant HIV infections
should be viewed as an achievable paradigm
and an essential part of the continuum of care
and support. j
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